Prevalence of 22q11.2 microdeletion syndrome in Iranian patients with cleft palate

Narges Nouri1, Mehrdad Memarzadeh2, Mansoor Salehi3

  • 1Isfahan Cleft Lip and Palate Clinic, Faculty of Rehabilitation, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Genetics and Molecular Biology, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.

Insights

22q11.2 microdeletion syndrome, a common genetic disorder, was found in 3.97% of Iranian infants with palatal anomalies. Submucous cleft palate or velopharyngeal incompetence combined with developmental delay may indicate the need for genetic testing.

Area of Science:

  • Genetics
  • Pediatrics
  • Medical Diagnostics

Background:

  • 22q11.2 microdeletion syndrome is a frequent genetic disorder linked to developmental issues, immune problems, and cleft palate.
  • Early diagnosis and treatment are crucial for managing this condition.
  • Identifying effective screening criteria for infants is essential.

Purpose of the Study:

  • To determine the prevalence of 22q11.2 deletion syndrome in Iranian infants with palatal anomalies.
  • To explore potential screening criteria for early identification of 22q11.2 deletion syndrome.

Main Methods:

  • A 5-year study involving 378 Iranian patients with palatal anomalies.
  • Patients included those with cleft palate only (CPO) and those with velopharyngeal incompetence (VPI) and/or submucous cleft palate (SMCP).
  • DNA copy number analysis was performed using multiplex ligation-dependent probe amplification (MLPA).

Main Results:

  • 15 out of 378 patients (3.97%) with palatal anomalies were diagnosed with 22q11.2 deletion.
  • The prevalence was significantly higher (14.42%) in syndromic patients.

Conclusions:

  • Submucous cleft palate (SMCP) or velopharyngeal incompetence (VPI) alongside other 22q11.2 deletion features, particularly developmental delay, may serve as effective criteria for molecular investigation.
  • These findings can aid in developing targeted screening strategies for early diagnosis.
Abstract

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.3K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
973
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
2.2K
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
868